NCT03551691View on ClinicalTrials.gov

Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI)

PHASE2CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

August 7, 2018

Primary Completion Date

November 2, 2022

Study Completion Date

November 2, 2022

Conditions
Pancreatic InsufficiencyCystic Fibrosis
Interventions
DRUG

Omeprazole 20mg Capsule

Omeprazole 20mg daily for 28 days

DRUG

Placebo oral capsule

Identically-appearing capsule to omeprazole for 28 days

Trial Locations (1)

19146

Children's Hospital of Philadelphia, Philadelphia

Sponsors

Collaborators (1)

Chiesi USA, Inc.
All Listed Sponsors
collaborator

Chiesi USA, Inc.

INDUSTRY

lead

Children's Hospital of Philadelphia

OTHER

NCT03551691 - Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI) | Biotech Hunter | Biotech Hunter